A recent study suggests that patients who stop using popular weight-loss injections like Mounjaro or Wegovy can put back on lost weight far faster than those who end traditional lifestyle programs.
Published data in a leading medical journal points out that while overweight people frequently drop substantial amounts of their body weight while on the medication, the mass returns at an estimated rate of 0.8 kg per month upon discontinuation.
"People buying these drugs need to be cognizant of the potential of fast rebound weight gain when the treatment ends," warns lead investigator Dr. Susan Jebb.
That rate of regain means a reversion to starting weight within about 18 months.
Comparing Treatments
The study, which looked at 37 of trials involving over 9,000 of participants, compared the results of GLP-1 agonists with other pills.
Scientists note that individuals who lose weight through diet and exercise typically see a less rapid creep back—approximately 0.1 kg a month—after stopping.
Understanding the Fast Rebound
Experts believe the mechanism of the jabs explains the heightened rebound.
GLP-1 drugs mimic a natural hormone called GLP-1, which moderates appetite.
"Sustained high doses of GLP-1 levels several times higher than normal might result in the body to generate a reduced amount of its own natural hormone, and could lessen sensitivity to its actions," said Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this GLP-1 'fix' leads to hunger is unsuppressed, making overeating a significant risk."
A Lifelong Disease?
Health authorities suggest the jabs for people with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
Professionals contend that, given the significant potential of relapse, the treatment might need to be life-long.
This perspective is echoed by drug manufacturers, who note that the results "highlight the chronic character of excess weight," similar to managing diseases like diabetes.
User Accounts
Users who have discontinued the jabs report a intense resurgence of cravings.
"I experienced a trigger activating and you're instantly extremely hungry," recalled an individual.
The struggle is exacerbated if individuals have not developed permanent dietary or behavioural modifications during therapy.
Growing Use
Survey data suggest that millions of people in the UK have tried these injections in the past year, with interest being substantial.
- Adoption is higher among females than men.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion access the medications through private healthcare rather than the NHS.
In conclusion, researchers caution that while the jabs are potent agents for shedding pounds, they are not a permanent solution and maintained weight loss likely depends on combined behavioural support.